[0008] Stereoisomers of the compounds of formula (I), and the pharmaceutical salts and solvates thereof, are also described. Methods of using compounds of formula (I) are described, as well as pharmaceutical compositions including the compounds of formula (I).

[0008a] In one aspect, there is provided a pharmaceutical composition comprising a compound as described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0008b] In another aspect, there is provided a use of a compound as described herein in the manufacture of a medicament for the treatment of cancer in a subject in need thereof, optionally wherein the cancer is urothelial carcinoma, breast carcinoma, endometrial adenocarcinoma, ovarian carcinoma, primary glioma, cholangiocarcinoma, gastric adenocarcinoma, non-small cell lung carcinoma, pancreatic exocrine carcinoma, oral, prostate, bladder, colorectal carcinoma, renal cell carcinoma, neuroendocrine carcinoma, myeloproliferative neoplasms, head and neck (squamous), melanoma, leiomyosarcoma, and/or sarcomas, or wherein the cancer is an intrahepatic cholangiocarcinoma; or wherein the cancer is an FGFR-mutant cancer.

[0008c] In yet another aspect, there is provided a use of a compound as described herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating achondroplasia, chondrodysplasia syndromes, hypochondroplasia (Hch), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), or thanatophoric dysplasia (TD) in a subject in need thereof.

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

[0009] The disclosure may be more fully appreciated by reference to the following description, including the following definitions and examples. Certain features of the disclosed compositions and methods which are described herein in the context of separate aspects, may also be provided in combination in a single aspect. Alternatively, various features of the disclosed compositions and methods that are, for brevity, described in the context of a single aspect, may also be provided separately or in any subcombination.

[0010] The term "optionally substituted," or "substituted" as used herein to describe a substituent defined herein, means that the substituent may, but is not required to be, substituted with one or more of: halo (i.e., -F, -Cl, -Br, -I), cyano, -OH, -C_1-C_6alkyl, C_3-C_6cycloalkyl, 3-7 membered heterocycloalkyl, -C_3-C_6spirocycloalkyl, 3-7 membered spiroheterocycloalkyl, bridged cycloalkyl, bridged heterocycloalkyl, C_2-C_6alkenyl, C_2-C_6 alkynyl, C_1-C_6haloalkyl (e.g., -CF_3; -CHF_2, -CH_2CF_3, and the like), -C_1-C_6alkoxy, -C_1-C_6 haloalkoxy (e.g., -OCF_3; -$OCHF_2$, -OCH_2CF_3, and the like), C_1-C_6alkylthio (e.g., -SCH_3; -SCH_2CH_3, and the like), C_1-C_6 alkylamino (e.g., -CH_2NH_2; -$CH_2CH_2NH_2$, and the like), -NH_2, -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, -NH(C_1-C_6 alkoxy), -C(O)NHC_1-C_6alkyl, -C(O)N(C_1-C_6 alkyl)$_2$, -COOH, -C_1-C_6alkylCOOH, -C_3-C_6cycloalkylCOOH, -C(O)NH_2, -C_1-C_6alkylCONH_2, -C_3-C_6cycloalkylCONH_2, -C_1-C_6alkylCONHC_1-C_6alkyl, -C_1-C_6alkylCON(C_1-C_6alkyl)$_2$, -C(O)C_1-C_6 alkyl, -C(O)OC_1-C_6 alkyl, -NHCO(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)C(O)(C_1-C_6 alkyl), -S(O)C_1-C_6 alkyl, -$S(O)_2C_1$-C_6 alkyl, oxo (i.e., =O), 6-12 membered aryl, or 5 to 12 membered heteroaryl groups. In other embodiments, "optionally substituted," or "substituted" means that the substituent may, but is not required to be, substituted with one or more of -C(O)(C_1-C_6haloalkyl), -$NHSO_2$(C_1-C_6alkyl), -N(C_1-C_6alkyl)SO_2(C_1-C_6alkyl), or -P(O)(C_1-C_6alkyl)$_2$ (*e.g.*, -P(O)$(CH_3)_2$). In some embodiments, each of the above optional substituents are themselves optionally substituted by one or two of these groups.